Platelet responses and coagulation activation on polylactide and heparin-polycaprolactone-L-lactide-coated polylactide stent struts

Journal of Biomedical Materials Research - Part A

Volumn 67, Issue 3, 2003, Pages 785-791

  Hietala, Eeva Maija ^a   Maasilta, Paula ^a   Välimaa, Tero ^b   Harjula, Ari L J ^a   Törrnälä, Pertti ^b   Salminen, Ulla Stina ^a   Lassila, Riitta ^a,c  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c WIHURI RESEARCH INSTITUTE   (Finland)

Author keywords

Heparin coating; Intravascular; Polylactide; Stent; Thrombosis

Indexed keywords

BIODEGRADATION; CHEMICAL ACTIVATION; DEPOSITION; KETONES; SCANNING ELECTRON MICROSCOPY; STAINLESS STEEL;

STENT TECHNOLOGY;

COAGULATION;

DEXTRO PHENYLALANYLPROLYLARGINYL CHLOROMETHYL KETONE; FIBRINOGEN; HEPARIN; LACTONE DERIVATIVE; POLYCAPROLACTONE; POLYLACTIDE; PROTHROMBIN; SEROTONIN; STAINLESS STEEL; THROMBIN ANTITHROMBIN COMPLEX; TRITIUM;

ARTICLE; BIOCOMPATIBILITY; BLOOD CLOTTING; CELL ADHESION; CELL STRUCTURE; DENSITY; GEL FILTRATION; HUMAN; HUMAN CELL; NORMAL HUMAN; SCANNING ELECTRON MICROSCOPY; STENT; THROMBIN TIME; THROMBOCYTE; THROMBOCYTE RICH PLASMA;

EID: 0346754914     PISSN: 00219304     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbm.a.10154     Document Type: Article

References (40)

1. Dormandy JA, Rutherford RB, Bakal C, Becker G, Clement DL, Cronenwett J, Durand-Zaleski I, Diehm C, Harris K, Hiatt WR, Hunink M, Isner J, Lammer J, Norgren L, Novo S, Ricco JB, Verstraete M, White J. Management of peripheral arterial disease (PAD). Transatlantic inter-society concensus (TASC). Aortoiliac stents. J Vasc Surg 2000;31(S):101-103.
2. Holmes DR, Hirshfeld J, Faxon D, Vlietstra R, Jacobs A, King SB III. ACC expert consensus document on coronary artery stents. J Am Coll Cardiol 1998;32:1471-1482.
3. Kovar LI, Monrad ES, Sherman W, Kunchithapatham S, Ravi KL, Silverman G, Brown DL. A randomized trial of stenting with or without balloon predilatation for the treatment of coronary artery disease. Am Heart J 2001;142:E9.
4. Krone RJ, Kimmel SE, Laskey WK, Klein LW, Schechtman KB, Cosentino A, Babb JD, Weiner BH. Evaluation of the society for coronary angiography and interventions' lesion classification system in 14,133 patients with percutaneous coronary interventions in current stent era. Cathet Cardiovasc Interv 2001;55:1-7.
5. Kolarov P, Tschoepe D, Nieuwenhuis HK, Gries FA, Strauer B, Schultheiss HP. PTCA: Periprocedual platelet activation. Part II of the Dusseldorf PTCA platelets study (DPPS). Eur Heart J 1996;17:1216-1222.
6. Inoue T, Sakai Y, Fujito T, Hoshi K, Hyashi T, Takayanagi K, Morooka S, Sohma R. Expression of activation-dependent platelet membrane protein after coronary stenting: A comparison with balloon angiography. Circulation 1996;94(S):1-260.
7. Zidar J, Lincoff A, Stack R. Biodegradable stents. In: Topol LJ, editor. Textbook of interventional radiology, 2nd ed. Philadelphia: Saunders; 1994, p 787-802.
8. Colombo A, Karvouni E. Biodegradable stents. "Fulfilling the mission and stepping away." Editorial. Circulation 2000;102:371-373.
9. Bos R. Poly(L-lactide) osteosynthesis-development of bioabsorbable bone plates and screws. Doctoral thesis, University of Groningen, The Netherlands; 1989.
10. Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S, Komori H, Tsuji T, Motohara S, Uehata H. Initial and 6-month results of biodegradable poly-1-lactic acid coronary stents in humans. Circulation 2000;102:399-404.
11. De Scheerder I, Wang K, Wilczek K Meuleman D, Van Amsterdam R, Vogel G, Piessens J, Van de Werf F. Experimental study of thrombogenecity and foreign body reaction induced by heparin-coated coronary stents. Circulation 1997;95:1549-1553.
12. Seifert B, Groth TH, Herrmann K, Romanuik P. Immobilization of heparin on polylactide for application to degradable biomaterials in contact with blood. J Biomater Sci Polym Ed 1995;7:277-287.
13. Seifert B, Romanuik P, Groth TH. Covalent immobilization of hirudin improves the haemocompatibility of polylactidepolyglycolides in vitro. Biomaterials 1997;18:1495-1502.
14. Blezer R, Cahalan L, Cahalan PT, Lidhout T. Heparin coating of tantalum coronary stents reduces surface thrombin generation but not factor Ixa generation. Blood Coag Fibrinol 1998;9:435-440.
15. Hiljanen-Vainio MP, Orava PA, Seppälä JV. Properties of ε-caprolactone/DL-lactide (ε-CL/DL-LA) copolymers with a minor ε-CL content. J Biomed Mater Res 1997;34:39-46.
16. Hietala EM, Salminen US, Ståhls A, Välimaa T, Maasilta P, Törmälä P, Nieminen MS, Harjula ALJ. Biodegradation of the copolymeric polylactide stent. Long-term follow-up in a rabbit aorta model. J Vasc Res 2001;38:361-369.
17. Siljander P, Lassila R. Studies of adhesion-dependent platelet activation: distinct roles for different participating receptors can be dissociated by proteolysis of collagen. Arterioscler Thromb Vasc Biol 1999;19:3033-3043.
18. Timmons S, Hawiger J. Isolation of human platelets by albumin gradient and gel filtration. Methods Enzymol 1989;169:11-21.
19. Mustonen P, Lassila R. Epinephrine augments platelet recruitment to immobilized collagen in flowing blood-Evidence for a von Willebrand factor-mediated mechanism. Thromb Haemost 1996;75:175-181.
20. Seth S, Litvack F, Dev V, Fishbein MC, Forrester JS, Eigler N. Subacute thrombosis and vascular injury resulting from slotted-tube nitinol and stainless steel stents in a rabbit carotid artery model. Circulation 1996;94:1733-1740.
21. Violaris AG, Ozaki Y, Serruys PW. Endovascular stents: A break through technology future challenges. Int J Card Imaging 1997;13:3-13.
22. van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR Jr, Ellis SG, Topol EJ. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary artery. Circulation 1996;94:1690-1697.
23. Lincof AM, Furst JG, Ellis SG, Tuch RJ, Topol EJ. Sustained local delivery of dexamethasone by a novel intravascular stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol 1997;29:808-816
24. Herrmann R, Schmidmaier G, Märkl B, Resch A, Hähnel I, Stemberger A, Alt E. Antithrombogenic coating of stents using a biodegradable drug delivery technology. Thromb Haemost 1999;82:51-57.
25. Sanchez J, Elgue G, Riesenfeld J, Olsson P. Control of contact activation on end-point immobilized heparin: The role of antithrombin and the specific antithrombin-binding sequence. J Biomed Mater Res 1995;29:655-661.
26. Blezer R, Fouache B, Willems GM, Lindhout T. Activation of blood coagulation at heparin-coated surfaces. J Biomed Mater Res 1997;37:108-113.
27. Knight CJ, Panesar M, Wilson DJ, Patrineli A, Chronos N, Wright C, Clarke D, Patel D, Fox K, Goodall AH. Increased platelet responsiveness following coronary stenting. Heparin as a possible aetiological factor in stent thrombosis. Eur Heart J 1998;19:1239-1248.
28. Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fractions on platelet aggregation J Clin Invest 1980;65:64-73.
29. Brace LD, Issleib S, Fareed J. Heparin-induced platelet aggregation is inhibited by antagonists of the thromboxane pathway. Thromb Res 1985;39:533-539.
30. Nelson SR, deSouza NM, Allison DJ. Endovascular stents and stent-grafts: Is heparin coating desirable? CardioVasc Intervent Radiol 2000;23:252-255.
31. Yamawaki T, Shimokawa H, Kozai T, Miyata K, Higo T, Tanaka E, Egashira K, Shiraishi T, Tamai H, Igaki K, Takeshita A. Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J Am Coll Cardiol 1998;32:780-786.
32. Herdeg C, Oberhoff M, Karsch KR. Antiproliferative stent coatings: Taxol and related compounds. Semin Interv Cardiol 1998;3:197-199.
33. Klugherz BD, Lianos G, Lieuallen W, Kopia G, Papandreou G, Natrayan P, Levengood T, Sasseen B, Adelman S, Falotico R, Wilensky RL. Stent-based delivery of sirolismus for the prevention of restenosis. J Am Coll Cardiol 2000;35(S):58A.
34. Cox D, Anderson P, Roubin C, Chou C, Agrawal S, Cavender J. Effects of local delivery of heparin and methotrexate on neointimal proliferation in stented porcine coronary arteries. Coron Artery Dis 1992;3:237-248.
35. Azrin MA, Mitchel JF, Fram DB, Pedersen CA, Cartun RW, Barry JJ, Bow LM, Waters DD, McKay RG. Angioplasty/Atherectomy: Decreased platelet deposition and smooth muscle cell proliferation after intramural heparin delivery with hydrogel-coated balloons. Circulation 1994;90:433-441.
36. Gutowska A, Bae YH, Jacobs H, Mahammad F, Mix D, Feijen J, Kim SW. Heparin release from thermosensitive polymer coatings: In vivo studies. J Biomed Mater Res 1995;29:811-821.
37. Olsson E, Asko-Seljävaara S, Lassila R. Topically administered macromolecular heparin proteoglycans inhibit thrombus growth in microvascular anastomoses. Thromb Haemost 2002;87:245-251.
38. Siljander P, Carpen O, Lassila R. Platelet-derived microparticles associate with fibrin during thrombosis. Blood 1996;87:4651-4663.
39. Beythien C, Gutensohn K, Bau J, Hamm CW, Kuhnl P, Meinertz T, Terres W. Influence of stent length and heparin coating on platelet activation: A flow cytometric analysis in a pulsed floating model. Thromb Res 1999;94:79-86.
40. Casarella WJ, Wilner GD. Guide wire thrombogenity measured by fibrinopeptide A radioimmunoassay. Am J Roentgenol 1977;128:363-366.